A Phase IIa, multicentre, randomised, doubleblind, placebo controlled, clinical study investigating the safety, tolerability and pharmacokinetics of two different infusion doses over 72 hours of a new regimen and new formulation of MCI186 in subjects with acute ischemic stroke.

Trial Profile

A Phase IIa, multicentre, randomised, doubleblind, placebo controlled, clinical study investigating the safety, tolerability and pharmacokinetics of two different infusion doses over 72 hours of a new regimen and new formulation of MCI186 in subjects with acute ischemic stroke.

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Jun 2014

At a glance

  • Drugs Edaravone (Primary)
  • Indications Stroke
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Mitsubishi Tanabe Pharma Corporation
  • Most Recent Events

    • 03 Mar 2011 Actual end date (November 2010) added as reported by ClinicalTrials.gov.
    • 03 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top